Author

M. Cipolla

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 8 Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 12 Research Focus:host-pathogen & immune response· 12 Assay:proteomics· 10 Organism:human· 8 Research Focus:cell type annotation· 3 Research Focus:clustering· 2 Research Focus:differential expression· 1 Assay:flow cytometry· 1

Frequent Co-Authors

A. Gazumyan· 12 shared F. Muecksch· 11 shared T. Hatziioannou· 11 shared C. Gaebler· 10 shared F. Schmidt· 10 shared M. C. Nussenzweig· 10 shared M. Caskey· 10 shared Z. Wang· 10 shared

Activity by Year

2020-2022 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

12 shared papersImmunology

A. Gazumyan

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins

Z. Wang, F. Muecksch, A. Cho, C. Gaebler, H.-H. Hoffmann, V. Ramos, S. Zong, M. Cipolla, B. Johnson, F. Schmidt, J. DaSilva, E. Bednarski, T. B. Tanfous, R. Raspe, K. Yao, , M. C. Nussenzweig

The paper identifies conserved neutralizing epitopes on the N-terminal domain of SARS-CoV-2 spike proteins using NTD-specific probes and characterizes antibodies that neutralize multiple variants.

bioRxiv · Feb 1, 2022 · PreprintImmunology

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

A. Cho, F. Muecksch, D. Schaefer-Babajew, Z. Wang, S. Finkin, C. Gaebler, V. Ramos, M. Cipolla, P. Mendoza, M. Agudelo, E. Bednarski, J. DaSilva, I. Shimeliovich, J. Dizon, M. Daga, , M. C. Nussenzweig

This study examines memory B cell evolution 5 months after mRNA vaccination in naive individuals, finding increased neutralizing activity but no further breadth or potency, and higher overall plasma neutralizing potency compared to natural infection.

bioRxiv · Jul 29, 2021Immunology

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year

Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.- H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. D. Silva, E. Bednarski, , M. C. Nussenzweig

This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.

bioRxiv · May 7, 2021Immunology

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

F. Muecksch, Y. Weisblum, C. Barnes, F. Schmidt, D. Schaefer-Babajew, J. Lorenzi, A. Flyak, A. DeLaitsch, K. Huey-Tubman, S. Hou, C. Schiffer, C. Gaebler, Z. Wang, J. Da Silva, D. Poston, , P. Bieniasz

This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.

bioRxiv · Mar 7, 2021 · PreprintMicrobiology

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, , M. C. Nussenzweig

This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.

Nature · Feb 10, 2021Peer-reviewedImmunology

Evolution of Antibody Immunity to SARS-CoV-2

C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, A. Hurley, M. Turroja, , R. Patel

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

bioRxiv · Nov 3, 2020Immunology

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

A. Schaefer, F. Muecksch, J. C. C. Lorenzi, S. R. Leist, M. Cipolla, S. Bournazos, F. Schmidt, A. Gazumyan, R. S. Baric, D. F. Robbiani, T. Hatziioannou, J. V. Ravetch, P. D. Bieniasz, M. C. Nussenzweig, T. P. Sheahan

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

bioRxiv · Sep 15, 2020Microbiology

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, C. Viant, C. Gaebler, M. Cipolla, H.-H. Hoffman, T. Y. Oliveira, D. A. Oren, V. Ramos, L. Nogueira, E. Michailidis, D. F. Robbiani, A. Gazumyan, , M. C. Nussenzweig

This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.

bioRxiv · Sep 9, 2020 · PreprintImmunology

A Broadly Neutralizing Macaque Monoclonal Antibody Against the HIV-1 V3-Glycan Patch

Z. Wang, C. O. Barnes, R. Gautam, J. C. Cetrulo Lorenzi, C. T. Mayer, T. Y. Oliveira, V. Ramos, M. Cipolla, K. M. Gordon, H. B. Gristick, A. P. West, Y. Nishimura, H. Raina, M. S. Seaman, A. Gazumyan, , M. C. Nussenzweig

This paper reports a broadly neutralizing monoclonal antibody from a macaque infected with SHIVAD8 that targets the V3-glycan patch of HIV-1 Env, showing neutralizing activity and protective efficacy in vivo.

bioRxiv · Aug 10, 2020Immunology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

bioRxiv · Jul 21, 2020Microbiology

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis, J. C. C. Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, , P. D. Bieniasz

The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.

bioRxiv · Jun 8, 2020Microbiology

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

bioRxiv · May 13, 2020Immunology